Skip to main content
Signal8

Protagenic Therapeutics, Inc.\new (PTIX) Form 8-K — Nov 17, 2026

$PTIXForm 8-KItems 1.01, 3.02, 7.01, 9.01Filed Nov 17, 2026, 4:41 PM ET0001493152-26-052871Original filing

Protagenic Therapeutics closed the initial tranche of a private placement on November 17, 2026, raising approximately $1.5 million gross at $0.61 per share — a price set at 90% of the trailing 30-day VWAP. Each share came with Series A warrants ($0.67 exercise) and Series B warrants ($0.73 exercise), each covering 100% of the shares purchased, so potential dilution roughly triples the headline share count if all warrants are exercised. The offering can run to $3 million (expandable to $5 million) through December 31, 2026, with Brookline Capital Markets earning a 7% cash fee, 1% expense allowance, and 7% warrant coverage.

Key figures

Gross Proceeds
1500000
Offering Price
0.61
Shares Offered
2459014
Price vs vwap
90% of 30-day VWAP
Warrant expiry
5 years, or earlier on 200% VWAP trigger or 10th GAD patient dosed
Maximum offering amount
$3,000,000 (may increase to $5,000,000)
Placement agent fee pct
7
Placement agent expense cap
75000
Series a warrant exercise price
0.67
Series b warrant exercise price
0.73
Non accountable expense allowance pct
1

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.